Press Releases

DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
DiaMedica Announces Pricing of Initial Public Offering and Nasdaq Listing
RSS
Show All